



LIQUID BIOPSY CANCER SCREENING Get an INSIGHT into your health today



Why should we screen for cancer?

As illnesses manifest prior to displaying symptoms, the onset of cancer symptoms is frequently not evident until a later stage.

Cancer has the potential to impact anyone, with statistics indicating that 1 in 2 women and 1 in 3 men will experience cancer during their lifetime.¹

The timely detection of cancer can significantly impact outcomes, as early identification facilitates more effective treatment, making it easier to manage the disease.





What is Lucence **INSIGHT**[™]?

LucenceINSIGHT[™] is a multi-cancer early detection(MCED) tool that screens for the signal of multiplecancers in one simple blood draw.



LucenceINSIGHT[™] is based on a proprietary ampliconbased technology to screen for the signal of cancer with a specificity of 99.2%. The test detects cancer-associated alterations circulating in blood. Advanced sequence analysis predicts the site of origin. The report will present your result as Areas of Concern, with an accuracy of 90%.



LucenceINSIGHT[™] is recommended for use in conjunction with existing screening tools for individuals without a personal history of cancer.

What results can I expect?

If result shows "Cancer Signal: Detected"?

Recommended to consult your doctor for further evaluation If result shows "Cancer Signal: Not Detected"? To continue following routine screening recommended by your healthcare provider. Cancer symptoms often do not visibly appear in the body until later. Cancer can affect any of us. Detecting cancer early enough can make a difference because cancer is easiest to treat when it is found early.

Learn more about Liquid Biopsy Cancer Screening

Liquid Biopsy Cancer Screening LucenceINSIGHT[™] - \$2800 | LucenceINSIGHT[™] PLUS - \$4200

How does LucenceINSIGHT[™] work?

EI	EI.
Ð	Ð
_	-

2 tubes of blood (~18mL) are required.

Evaluates the signal of 10 common types of cancer in Asia, including lung, breast and the colorectum.



Proprietary Next Generation Sequencing approach to increase screening sensitivity.



Screening for viruses such as EBV (Epstein-Barr virus) which is an associated pathogen of cancer.

This pamphlet is not intended for the purpose of providing medical advice.

All information, content, and material of this pamphlet are for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider.

Always seek the advice of your physician or other qualified healthcare provider for information you may need regarding a medical condition.

LUCENCEINSIGHT"

Available in the following panels:

	LUCENCE	
	\checkmark	\checkmark
BREAST	\checkmark	\checkmark
	\checkmark	\checkmark
PROSTATE	\checkmark	\checkmark
DV LIVER	\checkmark	\checkmark
, NOSE	\checkmark	\checkmark
BILE DUCT	\checkmark	\checkmark
PANCREAS	\checkmark	\checkmark
CONTE MYELOID	\checkmark	
CHRONIC MYELOID	\checkmark	

LucenceINSIGHT" PLUS also covers the following

CHIP*

 \checkmark

* Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related bone marrow phenomenon associated with both an increased risk of developing cardiovascular disease and hematologic cancers.

References

- 1. American Cancer Society. https://www.cancer.org
- 2. National Cancer Institute. https://seer.cancer.gov/
- 3. Pek M. et al. J Clin Oncol 2023 41:16_suppl, 3052-3052.



SKIP THE QUEUE, BOOK YOUR APPOINTMENT TODAY



info@bethesda.com.sg

www.bethesdamedical.com.sg

VISIT OUR WEBSITE FOR MORE INFORMATION

v29Nov2023